GLP 3 (RT) / CAG (12mg / 3mg)
For Research Use Only — Not for Human Use
Intended for laboratory research use only (e.g., analytical and in-vitro studies). Not for human use.
GLP 3 (RT) / CAG is a dual-peptide research blend combining a GIP/GLP-1/glucagon triple-receptor agonist (GLP 3 (RT)) with a long-acting amylin analog (CAG).
Researchers use this combination to study the interaction between incretin-receptor signaling and amylin-receptor pathways under controlled laboratory conditions.
This compound is provided by GENIQ exclusively for scientific research and not for human or animal use.
$199.99
-
Official retailer -
Quality guaranteed
-
Free delivery from $99
-
Free returns is available
What Is GLP 3 (RT) / CAG?
GLP 3 (RT) / CAG is a synthetic peptide blend developed for research on complementary metabolic signaling pathways.
GLP 3 (RT) is engineered to engage GIP, GLP-1, and glucagon receptors simultaneously. CAG is an acylated analog of amylin, a pancreatic hormone co-secreted with insulin, designed for extended duration within experimental systems.
Researchers use this blend to investigate how incretin-receptor activation and amylin-receptor activation interact in models of glucose regulation, gastric-emptying signaling, and energy balance.
GENIQ provides this compound solely for controlled laboratory research, not for human or animal use.
Peptide Overview
This blend merges two peptides commonly used in metabolic signaling research:
GLP 3 (RT):
A 39-amino-acid triple agonist studied for its simultaneous activity at GIP, GLP-1, and glucagon receptors and its influence on nutrient-sensing and energy-expenditure models.
CAG:
A long-acting amylin analog investigated for amylin- and calcitonin-receptor signaling, satiety-circuit modeling, and gastric-emptying regulation in preclinical studies.
| Laboratory studies evaluate how this peptide combination may influence: |
| • Incretin-receptor and amylin-receptor co-activation |
| • Glucose-regulation and glucagon-suppression models |
| • Hypothalamic and brainstem satiety-signaling circuits |
| • Energy-balance pathways in preclinical models |
| These findings are strictly from research environments. |
All findings remain limited to preclinical and in-vitro experimental environments.
History of GLP 3 (RT) / CAG
CAG was developed as a lipidated amylin analog engineered to resist aggregation and extend duration, building on earlier research with pramlintide and native amylin. Its receptor profile spans amylin and calcitonin receptors.
GLP 3 (RT) was developed as a triple agonist, adding glucagon-receptor activity to the GIP/GLP-1 framework used in earlier incretin research.
Researchers began pairing incretin-based peptides with amylin analogs to explore whether the two hormone systems act through complementary mechanisms. The GLP 3 (RT) / CAG combination extends this line of inquiry in in-vitro and preclinical models of metabolic regulation.
Peptide Structure
GLP 3 (RT):
39-amino-acid GIP/GLP-1/glucagon receptor triple agonist with a C20 fatty-diacid side chain
Molecular Formula: C221H342N46O68
CAG:
Acylated 37-amino-acid amylin analog with a C20 fatty-diacid side chain, incorporating calcitonin-derived residue substitutions for stability
Certificates of Analysis
GLP 3 (RT) / CAG (12mg / 3mg)
Research Findings
Research models analyzing the dual activity of GLP 3 (RT) and CAG commonly explore:
| • Incretin and amylin pathway interactions: Studying combined receptor signaling when both hormone systems are activated. |
| • Glucose-regulation modeling: Examining insulin-secretion, glucagon-suppression, and glucose-disposal responses in preclinical models. |
| • Satiety-circuit signaling: Investigating hypothalamic and area-postrema responses to amylin-receptor activation. |
| • Receptor pharmacology: Assessing binding kinetics, cAMP accumulation, and downstream gene-expression changes in vitro. |
| These data represent controlled in-vitro and preclinical studies, not clinical outcomes. |
These findings reflect laboratory experiments only and do not indicate clinical outcomes.
References
FAQ
Are GENIQ peptides pharmaceutical products?
No. They are not drugs, supplements, or therapeutic items. All compounds are provided strictly for laboratory research.
Who should purchase GENIQ research materials?
Qualified researchers, laboratories, and institutions working within applicable laws and regulations.
Do orders include COAs?
Yes. Each peptide includes a Certificate of Analysis confirming identity and purity testing when available for that lot.
What handling notes does GENIQ provide?
Only storage temperature and solvent-compatibility notes when listed on the product page. GENIQ does not provide guidance on preparation or application. Buyers follow their institution’s laboratory protocols.
Are these products for human use?
No. For Research Use Only — Not for Human Use. Not for human or animal consumption.
For Research Use Only — Not for Human Use
Sold exclusively as laboratory research materials. Not for human or animal consumption, clinical use, or household use.
Intended research use: Laboratory and in-vitro research, including analytical characterization and pathway / receptor-binding studies as applicable to this compound. Not for human consumption, clinical use, or diagnostic use on humans.
GLP 3 (RT) / CAG is a dual-peptide research blend combining a GIP/GLP-1/glucagon triple-receptor agonist (GLP 3 (RT)) with a long-acting amylin analog (CAG).
Researchers use this combination to study the interaction between incretin-receptor signaling and amylin-receptor pathways under controlled laboratory conditions.
This compound is provided by GENIQ exclusively for scientific research and not for human or animal use.
RELATED PRODUCTS
